In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species

Schwarz, Patrick; Dannaoui, Éric

doi:10.3390/jof6030103

Cited by 14 publications

(12 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Already prior to the COVID-19 pandemic repurposing of drugs had become trendy. Repurposed drugs have shown activity against bacteria 29 , yeasts 29,30 , and filamentous fungi [31][32][33][34] . Colistin is a drug of last resort with activity against multidrug-resistant gram-negative bacteria such as Pseudomonas aeruginosa, Klebsiella pneumoniae, or Acinetobacter baumanii 35 ; but colistin has also shown to damage the cell membrane of C. albicans 17 , which could make it an interesting partner in combination therapy against multidrug-resistant C. auris infections.…”

Section: Discussionmentioning

confidence: 99%

In vitro synergy of isavuconazole in combination with colistin against Candida auris

Schwarz

Bidaud

Dannaoui

2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

The in vitro interactions of isavuconazole with colistin were evaluated against 15 clinical Candida auris isolates by a microdilution checkerboard technique based on the EUCAST reference method for antifungal susceptibility testing and by agar diffusion using isavuconazole gradient concentration strips with or without colistin incorporated RPMI agar. Interpretation of the checkerboard results was done by the fractional inhibitory concentration index and by response surface analysis based on the Bliss model. By checkerboard, combination was synergistic for 93% of the isolates when interpretation of the data was done by fractional inhibitory concentration index, and for 80% of the isolates by response surface analysis interpretation. By agar diffusion test, although all MICs in combination decreased compared to isavuconazole alone, only 13% of the isolates met the definition of synergy. Essential agreement of EUCAST and gradient concentration strip MICs at +/− 2 log2 dilutions was 93.3%. Antagonistic interactions were never observed for any technique or interpretation model used.

show abstract

Section: Discussionmentioning

confidence: 99%

In vitro synergy of isavuconazole in combination with colistin against Candida auris

Schwarz

Bidaud

Dannaoui

2020

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…Previous reports demonstrated that spectrophotometric reading is a good alternative for Aspergillus spp. [ 33 , 34 , 35 ]. Incorporation of spectrophotometric reading leads to more objective MIC determination and automation of the process.…”

Section: Discussionmentioning

confidence: 99%

Colistin and Isavuconazole Interact Synergistically In Vitro against Aspergillus nidulans and Aspergillus niger

2020

Self Cite

View full text Add to dashboard Cite

The in vitro interactions of isavuconazole in combination with colistin were evaluated against 55 clinical Aspergillus species isolates belonging to the five most important species (Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, and Aspergillus terreus) responsible for human aspergillosis by a microdilution checkerboard technique based on the European Committee on Antimicrobial Susceptibility Testing (EUCAST) reference method for antifungal susceptibility testing. Selected isolates (A. nidulans, n = 10; A. niger, n = 15) were additionally evaluated by an agar diffusion assay using isavuconazole gradient concentration strips with or without colistin incorporated Roswell Parc Memorial Institute (RPMI) agar. Interpretation of the checkerboard results was done by the fractional inhibitory concentration index. Using the checkerboard method, combination isavuconazole–colistin was synergistic for 100% of the 15 A. nidulans isolates and for 60% of the 20 A. niger isolates. No interactions were found for any of the other isolates. By agar diffusion assay, minimal inhibitory concentrations (MICs) in combination decreased compared to isavuconazole alone for 92% of the isolates. No interactions were found for any A. nidulans isolates, but synergy was observed for 40% of the A. niger isolates. A poor essential agreement of EUCAST and gradient concentration strip MICs at ± 2 log2 dilutions with 0% was obtained. Antagonistic interactions were never observed regardless of the technique used.

show abstract

“… Kubiça et al ( 2016 ) Aspergillus spp. 0.25–16 Mice CAS High and Washburn ( 1997 ); Steinbach et al ( 2004 ); Kubiça et al ( 2016 ); Schwarz and Dannaoui ( 2020 ) Fusarium spp. 1–40 - CAS Shalit et al ( 2009 ) C. albicans No effects.…”

Section: Immunosuppressantsmentioning

confidence: 99%

“… 8 ISA Schwarz et al ( 2019 ) Phycomyces blakesleeanus 6.3-200 - CAS, ISA Bastidas et al ( 2012 ) Aspergillus spp. 16 Mice ISA High and Washburn ( 1997 ); Kontoyiannis et al ( 2003 ); Schwarz and Dannaoui ( 2020 ) Mycophenolic acid C. neoformans 30 Nematode AmB Disrupts de novo GTP biosynthesis. Morrow et al ( 2012 ); Banerjee et al ( 2014 ) C. albicans 0.25 - - Köhler et al ( 2005 ) Mizoribine C. albicans - - - Disrupt de novo GTP biosynthesis.…”

Section: Immunosuppressantsmentioning

confidence: 99%

Drug repurposing strategies in the development of potential antifungal agents

Zhang

Liu

Zeng

et al. 2021

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

The morbidity and mortality caused by invasive fungal infections are increasing across the globe due to developments in transplant surgery, the use of immunosuppressive agents, and the emergence of drug-resistant fungal strains, which has led to a challenge in terms of treatment due to the limitations of three classes of drugs. Hence, it is imperative to establish effective strategies to identify and design new antifungal drugs. Drug repurposing is a potential way of expanding the application of existing drugs. Recently, various existing drugs have been shown to be useful in the prevention and treatment of invasive fungi. In this review, we summarize the currently used antifungal agents. In addition, the most up-to-date information on the effectiveness of existing drugs with antifungal activity is discussed. Moreover, the antifungal mechanisms of existing drugs are highlighted. These data will provide valuable knowledge to stimulate further investigation and clinical application in this field. Key points • Conventional antifungal agents have limitations due to the occurrence of drug-resistant strains. • Non-antifungal drugs act as antifungal agents in various ways toward different targets. • Non-antifungal drugs with antifungal activity are demonstrated as effective antifungal strategies.

show abstract

In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus against Aspergillus Species

Cited by 14 publications

References 51 publications

In vitro synergy of isavuconazole in combination with colistin against Candida auris

In vitro synergy of isavuconazole in combination with colistin against Candida auris

Colistin and Isavuconazole Interact Synergistically In Vitro against Aspergillus nidulans and Aspergillus niger

Drug repurposing strategies in the development of potential antifungal agents

Contact Info

Product

Resources

About